AI-generated from publicly available materials.The integration of artificial intelligence (AI) in the medical device sector is reshaping expectations around product development, emphasizing not just speed but also the reliability of results.
During a recent webinar featuring experts from Critical Software, IQ Inc., and Bausch + Lomb, the discussion highlighted the evolving demands from clients. Today, stakeholders seek transparency regarding AI's application in software development, focusing on how AI tools are utilized and the verification of their outcomes. As Barbara Vankirk, CEO of IQ Inc., noted, clients are increasingly asking detailed questions about AI's role in their projects, signaling a shift from mere software delivery to the assurance of software reliability throughout its lifecycle.
Experts emphasized the importance of clearly defining the problems AI aims to solve before implementation. Birpal Sachdev from Bausch + Lomb cautioned against adopting AI without a clear understanding of its potential value, stressing that data quality and readiness are critical for successful AI integration. He pointed out that a significant portion of project time often goes into data management, which is essential for effective AI deployment.
Moreover, the webinar underscored the distinction between using AI as a tool in the development process versus embedding it within the medical device itself. While the former focuses on enhancing development efficiency, the latter raises complex questions about safety and accountability. Experts urged for comprehensive verification processes that encompass the entire system rather than just the AI components, advocating for traceability and human oversight to ensure the reliability and safety of AI-driven decisions.
In conclusion, AI holds transformative potential for the MedTech industry, but its successful application requires disciplined processes, clear problem identification, and robust data management. Organizations must approach AI as a capability to be cultivated, ensuring that human expertise and accountability remain central to the development of safety-critical products.